Egan indicated all four indications—COVID-19, multiplex flu A/B, COVID-19 and RSV test, TB, and HPV—are expected to enter clinical trials during the remainder of 2025. "We anticipate to begin with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results